KR20130123947A - Immune enhancing and antiviral composition comprising extract of salvia miltiorrhiza bunge - Google Patents

Abstract

The present invention relates to an immunostimulatory and antiviral composition containing a Salvia miltiorrhiza extract and a method for enhancing immunity and antiviral activity in animals by administering the Salvia miltiorrhiza extract to animals exclusively of human, which need to enhance immunity. According to the present invention, the immunostimulatory and antiviral composition shows antiviral activity and enhances immunity, thereby being applied for preventing and treating disease infected by bacteria and virus and being widely used as a medicine or a health food for enhancing and regulating immunity in a patient whose immunity is reduced or suppressed and an immunostimulatory and antiviral feed for strengthening ant-disease immunity in animals. Also, the immunostimulatory and antiviral composition hardly cause toxicity or side effects, thereby being used for long-term administration with safety for the purpose of prevention. [Reference numerals] (AA) Survival rate (%);(BB) Salvia miltiorrhiza;(CC) Control group;(DD) Number of days after infection

Description

FIELD OF THE INVENTION [0001] The present invention relates to an immunological enhancing and antiviral composition comprising extracts of Panax ginseng CA Meyer,

The present invention relates to an immunostimulatory and antiviral composition, and more particularly, to an immunostimulatory and antiviral composition comprising a ginseng extract which can be used as a medicament, a health functional food, a feed composition or the like.

Immunity can be divided into innate immunity, which has been born since birth, and acquired immunity, which is obtained by adapting to life after being acquired. Congenital immunity is also called "natural immunity" and is characterized by nonspecific responses to antigens and no special memory effect.

In recent years, the most important research field of the innate defense immune system in vivo is the field of innate immunity induced by interferon, and activation of such interferon mediated immunity may be a fundamental preventive method against various infectious disease pathogens. Therefore, studies on the interferon activation mechanism and the development of immunomodulators capable of inducing interferon are active. In addition, as one of the defense mechanisms of innate immunity following infection of pathogens, immune factors (inflammatory cytokines) are secreted, and inflammatory reactions are induced by these factors to protect against pathogens. Therefore, inducing an appropriate level of inflammatory response may also be a prophylactic and treatment method for various infectious disease pathogens, and it is necessary to research and develop an immunostimulating agent that can induce it.

Virus refers to a toxic substance in Latin and refers to a group of infectious pathogenic particles passing through a bacterial filter paper (0.22㎛). Viruses may be classified as bacteriophage, plant viruses, or animal viruses according to host cell types, and may be classified as DNA viruses or RNA viruses according to nucleic acid types. Recently, various viral diseases such as swine flu, AI and foot-and-mouth disease caused social problems, and consequently, anxiety about effective measures for viral diseases has attracted great social attention.

Currently, the best way to prevent viral disease is vaccination. Nevertheless, in the case of diseases caused by RNA viruses, the efficiency of vaccines due to the generation of many virus serotypes (subtypes) is important. Development and dissemination of inhibitors for the prevention of viruses that can supplement the problems of such vaccines is an important matter, and for this purpose, preventive agents that enhance the immunity of individual animals by stimulating the innate innate immune system, which is the initial defense system against viruses. Discovery and development can be an important method of drug development.

Representative antiviral agents that inhibit the growth of influenza viruses include amantadine and rimantadine, but these two antiviral agents are effective only against serotype A influenza virus and serotype B without M2 protein. It was found to be ineffective against the influenza virus. In addition, amantadine and rimantadine have been found to have a disadvantage in that the mutant virus, which does not affect the ion channel function of the influenza virus M2 protein, appears very easily. To alleviate this drawback, zanamivir and oseltamivir have been developed as effective antiviral agents for all 16 serotype A influenza viruses and serotype B influenza viruses. However, zanamivir has the disadvantage of inhalation and intravenous administration, while oseltamivir is orally available, but has been pointed out as a disadvantage due to side effects such as recent reports of the emergence of resistant virus and vomiting and dizziness upon oral administration.

In addition, vaccines against Newcastle Disease virus are classified into virulence vaccine and Sadox vaccine. It is known that the most widely used Newcastle disease virulence vaccine, B1 strain and La Sota strain (including Clone strain) The multivitamins combined vaccine oil vaccine, a Newcastle Disease vaccine that is used globally, can prevent three or more diseases at the same time by a single vaccination. However, in the case of laying hens farms, cases of Newcastle disease caused by immunity reduction are increasing.

In addition, the main control method of vesicular stomatitis virus is the complete treatment of the disease, so as with foot-and-mouth disease, prevention and blocking prevention and eradication of susceptible domestic livestock are the best methods.

Under these circumstances, many efforts have been made to overcome the shortcomings of the existing antiviral preparations in Korea and abroad. As one of the efforts, researches on the antiviral efficacy of herbal extracts and plant extracts are actively conducted in Korea. .

Salvia miltiorrhiza BUNGE belongs to the perennial plant belonging to the family Lamiaceae. The components known to be contained in the roots include flavonoids such as baicalin, isotanshione I, triterpenes such as diterpenes, oleanolic acid and triterpenes such as tanshinone I, cinnamon IIA, cinnamon IIB and cryptotanshinone, rosmarinic acid, And lignans such as phenylpropanoids, salvianolic acid, and lithospermic acid B, and the like. Among the diterpene compounds, isotansinone I, carcinogen I, carcinogen IIA, carcinogen IIB, and cryptotancinone are the components contained only in radish. Background Art [0002] The prior art using Dansamp is mainly directed to a composition for the treatment and prevention of liver diseases, and to an effect on hepatocytes such as a composition for prevention and treatment of liver fibrosis or liver cirrhosis.

Accordingly, there is still a need for a composition using the extract of Dansamp extract which can overcome the disadvantages of existing antiviral agents and exert excellent immune enhancing effect and antiviral activity with little toxicity and side effects.

The inventors of the present invention completed the present invention by confirming that the extract of Dansamp was able to inhibit the proliferation of various RNA viruses by activating macrophages which are the main cells of innate immunity. The present invention relates to a pharmaceutical composition for preventing and treating various viruses or bacterial infectious diseases while securing long-term stability with little toxicity and side effects, It is an object of the present invention to provide an antiviral composition and a method for enhancing immunity and antiviral activity of an animal.

One aspect of the present invention for solving the above-mentioned problems provides a pharmaceutical composition for immune enhancement and antiviral treatment, which comprises extracts of Panax ginseng.

In addition, another aspect of the present invention provides a health functional food for immune enhancement and antiviral activity, which comprises extracts of Panax ginseng.

Yet another aspect of the present invention provides an immunostimulating and antiviral feed composition comprising a root extract.

Yet another aspect of the present invention provides immune enhancement and antiviral activity enhancement of an animal, comprising administering the extract to a subject in need thereof.

According to the present invention, it is possible to effectively apply to the prevention and treatment of various viruses and bacterial infectious diseases by using the extract of Radix Salviae which exerts excellent immunity enhancing effect, and can contribute to the enhancement of immunity.

In addition, the immunosuppressive and antiviral composition comprising the extract of Dansamp extract according to the present invention scarcely causes toxicity or side effects, so that it can be safely used for prophylactic purposes for a long period of time.

Therefore, the composition according to the present invention can be applied for the prevention and treatment of bacterial and viral infectious diseases, pharmaceutical compositions or functional foods for enhancing and regulating the immunity of patients with reduced or suppressed immunity, and anti-animal It can be widely used as a feed composition for immuno-enhancing for the purpose of strengthening the disease.

In addition, according to the present invention, it is possible to effectively and safely enhance the immunity of an animal by administering the extract of Dansampus to an animal necessary for immunity enhancement.

FIG. 1 shows the cytotoxicity test results of the extract of Radix Salviae Radix according to the example of the present invention.
FIG. 2 shows the results of the antiviral activity test on the PR8-gfp (Swine influenza virus) of the extracts of Rana ginseng according to the embodiment of the present invention.
FIG. 3 shows the results of an antiviral activity test for VSV-gfp (Vesicular stomatitis virus) of the extract of Rana ginseng according to an embodiment of the present invention.
FIG. 4 shows the results of an antiviral activity test for the NDV-gfp (Newcastle disease virus) of the extract of Rana ginseng according to an embodiment of the present invention.
FIG. 5 shows the results of the antiviral activity test according to the concentration of the ginseng extract according to an embodiment of the present invention.
FIG. 6 shows the results of induction of proinflammatory cytokines by the extracts of Panax ginseng according to an embodiment of the present invention.
FIG. 7 shows experimental results of induction of interferon-beta secretion by the extract of Panax ginseng according to the example of the present invention.
Figure 8 in accordance with an embodiment of the present invention shows an inhibition of influenza virus infection experiment result by the Salvia miltiorrhiza extract in vivo animal experiments.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.

The present invention is characterized by exhibiting an immunostimulating effect by using a ginseng extract which can activate macrophages, the main cells of innate immunity, and inhibit the proliferation of various RNA viruses.

The extract of Dansamp for use in the present invention can be generally formed by extraction using various solvents used for extracting natural products, for example, by one or more methods selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction .

In one embodiment, the extract is prepared by adding distilled water; Hydrothermal extraction at a temperature of 60 to 130 캜, preferably about 105 캜, for 30 to 240 minutes, preferably about 150 minutes; And it may be formed through a filtration step.

Dansamp extract has excellent antiviral activity against various viruses such as influenza virus, Newcastle disease virus and vesicular stomatitis virus. It strongly shows the immunity factor induction ability and increases the innate immune status of the individual, thereby increasing the infection and proliferation of influenza virus Suppressing effect.

In addition, the extract of Dansamp shows little cytotoxicity or side effects, so it can be safely used even when taken for a long time.

The present invention can be applied to a pharmaceutical composition for immunity enhancement and antiviral activity, a health functional food for immunity enhancement and antivirus, or a feed composition for immunity enhancement and antivirus, which comprises the extract of Dansamp extract exhibiting such efficacy.

One aspect of the present invention relates to a pharmaceutical composition for immunostimulating and antivirals that comprises extracts of Panax ginseng.

In one embodiment, the pharmaceutical compositions for the immunostimulant and antiviral of the present invention further comprise a pharmaceutically acceptable carrier, excipient or diluent.

Pharmaceutically acceptable carriers, excipients or diluents which can be used in the present invention are not particularly limited so long as they do not impair the effects of the present invention, for example fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, Sweeteners, fragrances, preservatives and the like.

Representative examples of pharmaceutically acceptable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium carbonate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable Ester, utopsol, macrogol, tween 61, cacao butter, lauridge, etc. are mentioned.

The pharmaceutical composition for immunostaining and antiviral of the present invention may be in the form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and injections.

The method of formulating the pharmaceutical composition may be carried out according to conventional methods known in the art, and is not particularly limited.

The pharmaceutical compositions for immunological enhancement and antiviral therapy of the present invention can be administered orally or parenterally. The dosage may be appropriately adjusted according to the age, sex, weight, condition, degree of disease, drug form, But generally about 5 to 500 mg / kg, preferably about 100 to 250 mg / kg, can be administered one to three times a day.

It will be apparent to those skilled in the art that the methods of administration, dosages, route of administration, constituents, etc. of the pharmaceutical composition for immunoenhancing and antiviral of the present invention can be suitably selected from conventional techniques known in the art.

The pharmaceutical composition for immunostaining and antiviral of the present invention can be used for the prevention and treatment of bacterial infectious diseases or viral infectious diseases.

In particular, the pharmaceutical composition for immune enhancement and antiviral treatment of the present invention contains the extract of Rana ginseng, which has little or no toxicity or side effects, as an active ingredient, so that it can be safely used for prophylactic purposes for a long period of time.

In one embodiment, the pharmaceutical composition for immuno-enhancement and antiviral use of the present invention may be used as an active ingredient in combination with a pharmacologically active ingredient in addition to the extract, or may be mixed with a pharmaceutical composition containing another active ingredient.

For example, the pharmaceutical compositions for immuno-enhancement and antiviral use of the present invention can be used for prevention or treatment of cancer, particularly prostate, colon, lung, breast, ovary, head and neck, vulvar and bladder cancer, glioma as well as non-communicable chronic diseases A pharmaceutical composition for the prevention or treatment of viral and bacterial infectious diseases, or a pharmaceutical composition for the treatment of autoimmune diseases and the like.

Another aspect of the present invention relates to a health functional food for immune-enhancing and antiviral treatment comprising extracts of Panax ginseng.

In one embodiment, the immunomodulatory and antiviral health functional food of the present invention further comprises a pharmaceutically acceptable food-aid additive.

Food acceptable acceptable food supplement additives which can be used in the present invention include sugars such as glucose, fructose, maltose, sucrose, dextrin, cyclodextrin and natural carbohydrates such as sugar alcohols such as xylitol, sorbitol, erythritol, tau Natural flavors such as martin and stevia extract, synthetic flavors such as saccharin, aspartame, colorants, pectic acid or salts thereof, alginic acid or salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents, and the like, but are not limited thereto.

The immunosuppressive and antiviral health functional food of the present invention may be in a form selected from the group consisting of powder, granule, tablet, capsule, candy, chewing gum, jelly and beverage.

The content of the ginseng extract in the immunoenhancing and antiviral health functional food may be appropriately selected in consideration of the form, flavor, taste, etc. of the food, and may be, for example, in the range of 0.01 to 30 wt% Lt; / RTI >

It is apparent to those skilled in the art that the form, composition and manufacturing method of the immunoenhancing and antiviral health functional food of the present invention can be suitably selected from conventional techniques known in the art.

Another aspect of the present invention relates to a feed composition for immunostimulating and antivirals comprising the extract of Panax ginseng.

The content of the ginseng extract in the feed composition for immunity enhancement and antiviral treatment may be appropriately selected according to species, age, body weight, rearing condition and the like of the feed livestock, and is 0.01 to 95% by weight, preferably 0.1 To 80% by weight.

The feed composition for immune enhancement and antiviral of the present invention may be prepared according to a feed preparation method known in the art, for example, after mixing various feed ingredients or blended feed with the extract of the present invention, and further processing It can be produced by further performing a process, for example, molding into pellets or cutting into granules and the like.

It will be apparent to those skilled in the art that the composition, composition, manufacturing method, feeding method, etc. of the immunostimulatory and antiviral feed composition of the present invention can be suitably selected from conventional techniques known in the art.

Another aspect of the present invention relates to the enhancement of immunity and antiviral activity of an animal, which comprises administering a root extract to an animal in need of immune enhancement other than human.

It is apparent to those skilled in the art that the dose, route of administration, administration time, etc. of the extract of Panax notoginseng can be suitably selected from conventional techniques known in the art in enhancing the immunity and antiviral activity of the animal of the present invention.

As described above, in the present invention, it is possible to prevent the growth of various RNA viruses by activating macrophages, and by using the extract of Ganoderma lucidum, which has little toxicity or side effects, in a pharmaceutical composition, a health functional food or a feed composition, Can exert a disease-strengthening effect, and can further provide an animal with enhanced immunity and antiviral activity.

Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are illustrative of the present invention, and the scope of the present invention is not limited to the following examples.

[ Example ]

1. Selection of medicinal materials

(1) Collection of medicinal materials

The antimicrobial activity and antimicrobial activity of the antimicrobial activity and antimicrobial activity of antimicrobial agents contained in the antimicrobial agent, antimicrobial activity, and antimicrobial activity were investigated.

(2) Preparation of herbal medicine extract

The extracted herbal extracts were subjected to hot water extraction at 105 ° C. for 150 minutes by adding 10 times of distilled water, followed by primary filtration at 0.45 μm and final filtration at 0.22 μm to remove precipitates. The pH was then adjusted to 7.0 and dispensed in 1 ml portions of 1.5 ml Ep-tubes and stored at −20 ° C. for use in all experiments.

2. Mouse Macrophage  Used Sansam  Cytotoxicity of extract

: In order to confirm the cytotoxicity of the extract, the safety experiment was carried out as follows.

(1) Cytotoxicity test method

1) Mouse macrophage cell line Raw 264.7 was cultured and used in the experiment.

2) Cells were cultured on a 12-well TC plate, and then added with the concentrations of 0.3%, 0.5%, 1% and 2%, respectively, of the radish extract (pH adjusted) prepared above in DMEM supplemented with 1% FBS Respectively.

3) Negative control was treated with DMEM supplemented with 1% FBS.

4) After 22-24 hours, the cells were stained with 0.4% tryphan blue to confirm apoptosis.

(2) Cytotoxicity test results

The results of the cytotoxicity test are shown in Fig. 1 as the cell survival rate by the concentration of Radix Salviae Radix extract. As can be seen from FIG. 1, the extracts of Dansamp showed no cytotoxicity against raw cells even at a concentration of 2% or more.

3. Mouse Macrophage  Used Sansam  Antiviral Activity Test of Extracts

: Antiviral activity of various RNA viruses, namely Influenza virus, Newcastle disease virus and Vesicular stomatitis virus, was tested as follows.

(1) Antiviral activity test method

1) Raw 264.7 mouse macrophage line was grown and used for the experiment (8 × 10 ⁵ cell / well)

2) Cells were cultured on a 12-well TC plate and treated with DMEM supplemented with 1% FBS at a concentration of 1%.

3) The negative control was treated only with DMEM added 1% FBS, the positive control was treated with Mouse IFN-B (500 units / ㎖).

4) After 12 hours of treatment, PR8-gfp (MOI: 0.5), VSV-gfp (MOI: 0.5) and NDV-gfp (MOI: 0.5) were inoculated respectively.

5) After 2 hours of inoculation, the inoculum was removed, washed three times with PBS, and the degree of virus infection was measured after 8-10 hours.

(2) Results of antiviral activity test

1) PR8-gfp (swine influenza virus) test result

Figure 2 shows the results of the antiviral activity for PR8-gfp. Figure 2 (a) shows GFP (green fluorescent protein) fluorescence image after 12 hours of infection, Figure 2 (b) shows GFP absorbance and Figure 2 (c) shows cell viability Control group, PR8-gfp: virus-infected group, and ginseng: ginseng extract-treated group).

From FIG. 2, it can be seen that the infection rate of influenza virus was remarkably lowered and the cell survival rate was also increased compared with the virus infection group as a result of pretreatment with the extract.

2) VSV-gfp (Vesicular stomatitis virus) test result

FIG. 3 shows the results of the antiviral activity test for VSV-gfp. Figure 3 (a) shows the GFP fluorescence image after 12 hours of infection, Figure 3 (b) shows the viral titer graph after 24 hours of infection, and Figure 3 (c) (PC: positive control, VSV-gfp: virus-infected group, Dansamp: treatment with Panax ginseng extract). Fig. 3 (d) shows the cell survival rate after 24 hours of infection.

As can be seen from FIG. 3, as a result of pretreatment with Radix Salviae Radix extract, the rate of vesicular stomatitis virus infection was remarkably decreased, the virus level was decreased, and the cell survival rate was also higher than the virus infection group.

3) NDV-gfp (newcastle disease virus) test result

Figure 4 shows the results of the antiviral activity test for NDV-gfp. Fig. 4 (a) shows the GFP fluorescence image after 12 hours of infection, Fig. 4 (b) shows the GFP absorbance after 24 hours of infection, and Fig. 4 (c) Control group, NDV-gfp: virus-infected group, and ginseng: radish extract treatment group).

As can be seen from FIG. 4, as a result of pretreatment with Radix Salviae Radix extract, the infection rate of Newcastle disease virus was remarkably decreased and the cell survival rate was also higher than that of virus infection group.

4. Sansam  Antiviral activity test according to concentration of extract

: The following experiment was carried out in order to confirm the antiviral activity according to the concentration of Radix Salviae Radix extract.

(1) Antiviral activity test method

1) Raw 264.7 mouse macrophage line was grown and used for the experiment (8 × 10 ⁵ cell / well)

2) Cells were cultured on a 12-well TC plate and then the extracts (pH adjusted) prepared above were added to DMEM supplemented with 1% FBS at concentrations of 0.1%, 0.2%, 0.5%, 1% and 2% .

3) Negative control group was treated with DMEM supplemented with 1% FBS, and positive control group was treated with Mouse IFN-B (500 units / ml).

4) PR8-gfp (swine influenza virus) was inoculated at a MOI level of 0.5 after 12 hours of treatment.

5) After 2 hours of inoculation, the inoculum was removed, washed 3 times with PBS, and the virus infection was measured 8 ~ 10 hours later.

(2) Results of antiviral activity test

FIG. 5 shows the antiviral activity according to the concentration of the extract of Ganoderma lucidum as a GFP fluorescence image. As can be seen from FIG. 5, the extracts of Panax ginseng showed antiviral activity similar to that of the positive control in a concentration-dependent manner.

5. Mouse Macrophage  Used Sweet ginseng  Proinflammatory cytokine induction ( pro -inflammatory Cytokine Induction ) Experiment

: Experiments were carried out as follows to confirm the induction effect of the extract of Dansamp.

(1) Proinflammatory cytokine induction experiment method

1) Raw 264.7 mouse macrophage line was grown and used for the experiment (8 × 10 ⁵ cell / well)

2) Cells were cultured on a 6-well TC plate and treated with DMEM supplemented with 1% FBS at a concentration of 1% of the extract prepared above (pH adjusted).

3) Negative control group was treated with DMEM supplemented with 1% FBS, and positive control group treated with lipopolysaccharide (LPS) powder (100ng / ml).

4) After treatment, the values of TNF-α, IL-6 and IL-12 were measured by ELISA for the results of 6 hours, 12 hours, 24 hours and 36 hours.

(2) Results of induction of proinflammatory cytokine

FIG. 6 shows the results of induction of proinflammatory cytokines by the extract of Panax notoginseng (NC: negative control group, LPS: positive control group; TNF-α is an immune and inflammatory mediator that activates macrophages and induces a variety of cytokine secretion. It stimulates B-cells and IL-12 promotes T-cell differentiation, And IL-6 is an important cytokine that activates B-cells to increase antibody production and promote antigen-specific immune responses.

From FIG. 6, it can be confirmed that the induction ability of proinflammatory cytokine from raw cells is strongly exhibited by the extract of Panax ginseng.

6. Mouse Macrophage  Used Sweet ginseng  Interferon-β Secretion Induction Experiment

: Experiments were carried out as follows to confirm the induction effect of the extract of Radix Salviae Radix.

(1) induction of interferon-β secretion Interferon -β secretion Induction Experimental Method

1) Raw 264.7 mouse macrophage line was grown and used for the experiment (8 × 10 ⁵ cell / well)

2) Cells were cultured on a 6-well TC plate and treated with DMEM supplemented with 1% FBS at a concentration of 1% of the extract prepared above (pH adjusted).

3) Negative control group was treated with DMEM supplemented with 1% FBS, and positive control group treated with lipopolysaccharide (LPS) powder (100ng / ml).

4) Interferon-β was measured by ELISA on the result obtained after 12 hours and 24 hours after treatment.

(2) Interferon-β secretion induction test results

FIG. 7 shows the results of induction of interferon-beta secretion by the extract of Panax ginseng (NC: negative control group, LPS: positive control group; Interferon-β is a cytokine secreted in response to foreign substances such as viruses and cancer cells, and is a substance that induces an immune response by causing intracellular anticancer and antiviral actions.

From FIG. 7, it can be confirmed that interferon-beta induction ability is shown from raw cells by the extract of Rawan extract.

7. In the mouse Sansam  Inhibition against Influenza Virus Infection by Extracts

(1) Experimental method

1) Divide the female Balb / c mice, 4-5 weeks old, into control group (5 animals) and ginseng extract-treated group (5 animals), respectively.

2) In the case of Dansamp group (5 animals), about 300 ㎕ of Dansamp extract was orally administered daily for 5 days, and the lethal dose of PR8 virus (10LD ₅₀ ) was administered to the nasal passages of control group and ginseng extract group , And in the group treated with dansamp extract, about 300 μl of the extract was administered orally daily for 5 days after the virus attack.

Mice were weighed every two days and survival experiments were performed until the mice died.

(2) Experimental results

FIG. 8 shows changes in weight (a) and survival rate (b) in mice as a result of inhibition of influenza virus infection by the extract of Panax ginseng. As shown in FIG. 8, only one mouse was killed and the weight change was recovered in the mouse of the group administered with the extract of Panax ginseng, while the control mice were all killed within 7 days after the virus attack.

These results suggest that the immune enhancing components in the extracts of Dansamp extract increase the innate immunity of mice and inhibit infection and proliferation of influenza virus.

8. Manufacturing example

(1) injections

The extract of Panax ginseng prepared in the above step 1: 100 mg

Sodium Metabisulfite: 3.0 mg

Methylparaben: 0.8 mg

Propylparaben: 0.1 mg

Sterile sterilized distilled water for injection:

The above ingredients were mixed and made into a final volume of 2 ml by a conventional method, filled in an ampoule and sterilized to prepare an injection.

(2) tablets

200 mg of the extract obtained from step 1 above

Potato starch: 100 mg

Lactose: 100 mg

Colloidal silicic acid: 16 mg

Magnesium Stearate: Appropriate

The ingredients were mixed and tableted according to a conventional tablet preparation method to prepare tablets.

(3) capsules

The extract of Panax ginseng prepared in the above step 1: 100 mg

Lactose: 50 mg

Starch: 50 mg

Talc: 2 mg

Magnesium Stearate: Appropriate

The capsules were prepared by mixing the ingredients and filling the gelatin capsules according to a conventional capsule production method.

(4) pills

The dried ginseng extract prepared in the above step 1: 120 mg

Corn Starch: 100 mg

Sterilized distilled water: suitable amount

The above ingredients were mixed and pelletized to spheres of appropriate size according to conventional pellet manufacturing methods to produce pellets.

(5) health food

1) health drink

The extracts prepared in the above item 1 were mixed in an appropriate amount and sterilized by a beverage such as oligosaccharide (2%), liquid fructose (0.5%), sugar (2%), salt (0.5% A beverage was prepared.

2) functional food

The functional food containing the extract of Radix Salviae Radix was prepared by mixing the extract of Radix Salviae Radix prepared in 1 above with various vitamins and mineral-containing functional foods.

(6) feed composition

The animal feed diets were mixed with the dried fish extract prepared in the above item 1 in an appropriate amount to prepare a feed composition, which was then pelletized and granulated.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments or constructions. Various changes, substitutions and alterations can be made hereto without departing from the spirit and scope of the invention. It will be clear to those who have knowledge.

Claims (13)

Immunity-enhancing and antiviral pharmaceutical composition comprising the extract of Salvia.
The method of claim 1,
The Salvia extract is characterized in that formed by at least one method selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction.
A pharmaceutical composition for immune enhancement and antiviral activity.
The method of claim 1,
It further comprises a pharmaceutically acceptable carrier, excipient or diluent
A pharmaceutical composition for immune enhancement and antiviral activity.
The method of claim 1,
The pharmaceutical composition is characterized in that the form is selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and injections
A pharmaceutical composition for immune enhancement and antiviral activity.
The method of claim 1,
Used for the prevention or treatment of bacterial or viral infectious diseases
A pharmaceutical composition for immune enhancement and antiviral activity.
Health functional foods for immune enhancement and antiviral containing Salvia extract.
The method according to claim 6,
The Salvia extract is characterized in that formed by at least one method selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction.
Immune enhancement and antiviral health functional food.
The method according to claim 6,
It further comprises a food acceptable food supplement additive
Immune enhancement and antiviral health functional food.
The method according to claim 6,
The health functional food is characterized in that the form selected from the group consisting of powder, granules, tablets, capsules, candy, chewing gum, jelly and beverages.
Immune enhancement and antiviral health functional food.
Immunity-enhancing and antiviral feed composition comprising the extract of Salvia.
The method of claim 10,
The Salvia extract is characterized in that formed by at least one method selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction.
Feed composition for immune enhancing and antiviral.
A method for enhancing immunity and antiviral activity of an animal comprising administering to the animal in need of immune boosting, extract of Salvia soybean.
The method of claim 12,
The Salvia extract is characterized in that formed by at least one method selected from the group consisting of hot water extraction, alcohol extraction and alcohol extraction.
Methods of Enhancing Immunity and Antiviral Activity in Animals.

Images